Form 4 for BBNX Beta Bionics, Inc.
Accepted 2026-01-07 00:00:00 ET · period of report 2026-01-06 · accession 0002048500-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-07 | 2026-01-06 | BBNX | Mensinger Mike | Chief Product Off | S - Sale | $30.10 | -2,200 | 80.8K | -3% | -$66.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-06 | S | D | 2,200 | $30.10 | 80,752 | D | — | — | (F2) The weighted average sale price for the transaction reported was $30.1005 and the range of prices were between $30.00 and $30.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |